Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study
- 1 October 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Glaucoma
- Vol. 15 (5), 349-353
- https://doi.org/10.1097/01.ijg.0000212260.04488.60
Abstract
The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol (Δ-9-THC) and cannabidiol (CBD). A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Δ-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Δ-9-THC, 20 mg CBD, 40 mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects. Two hours after sublingual administration of 5 mg Δ-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P=0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P=0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Δ-9-THC administration. A single 5 mg sublingual dose of Δ-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40 mg CBD produced a transient increase IOP rise.Keywords
This publication has 23 references indexed in Scilit:
- Cannabinoids and glaucomaBritish Journal of Ophthalmology, 2004
- Effect of WIN 55212-2, a Cannabinoid Receptor Agonist, on Aqueous Humor Dynamics in MonkeysAmerican Journal of Ophthalmology, 2003
- Cannabinoids in the treatment of glaucomaPharmacology & Therapeutics, 2002
- Therapeutic aspects of cannabis and cannabinoidsThe British Journal of Psychiatry, 2001
- The synthetic cannabinoid WIN55212‐2 decreases the intraocular pressure in human glaucoma resistant to conventional therapiesEuropean Journal of Neuroscience, 2001
- Direct and Indirect Approaches to Neuroprotective Therapy of Glaucomatous Optic NeuropathySurvey of Ophthalmology, 1999
- Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbitsLife Sciences, 1998
- Central Nervous System and Peripheral Mechanisms in Ocular Hypotensive Effect of CannabinoidsAmerican Journal of Ophthalmology, 1987
- Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerolExperimental Eye Research, 1984
- Intraocular pressure, ocular toxicity and neurotoxicity after administration of Δ9-Tetrahydrocannabinol or cannabichromeneExperimental Eye Research, 1984